As Thermo Fisher Scientific’s Oncomine Dx in-house NGS solutions go from strength to strength, so strengthens their vision of worldwide availability of ultra-rapid NGS-sequencing-based solutions.
In this interview with The Pathologist, Luca Quagliata reflects on Thermo Fisher Scientific’s history in precision medicine, the priorities driving their current strategy, and future predictions for the field.
Newsletters
Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.
